|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200057998 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-26 00:08:58 |
|
注册时间: Date of Registration: |
2022-03-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于针刺治疗ED选穴方案研究及疗效评价 |
|
Public title: |
Based on acupuncture treatment of ED acupoint selection program research and efficacy evaluation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于针刺治疗ED选穴方案研究及疗效评价 |
|
Scientific title: |
Based on acupuncture treatment of ED acupoint selection program research and efficacy evaluation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
ChiMCTR2200005763 |
|
申请注册联系人: |
全菲 |
研究负责人: |
崔瑾 |
|
Applicant: |
Quan Fei |
Study leader: |
Cui Jin |
|
申请注册联系人电话: Applicant telephone: |
+86 15585107127 |
研究负责人电话:
Study leader's |
+86 13985026278 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2417891021@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
516260179@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省贵阳市市东路50号 |
研究负责人通讯地址: |
贵州省贵阳市市东路50号 |
|
Applicant address: |
50 Shidong Lu, Guiyang city, Guizhou Province |
Study leader's address: |
50 Shidong Lu, Guiyang city, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州中医药大学 |
||
|
Applicant's institution: |
Guizhou University of Chinese Medicine |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2022031 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州中医药大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-01-07 00:00:00 | ||
|
伦理委员会联系人: |
刘洋 |
||
|
Contact Name of the ethic committee: |
Liuyang |
||
|
伦理委员会联系地址: |
贵州省贵阳市云岩区宝山北路71号 |
||
|
Contact Address of the ethic committee: |
71 Baoshan Bei Lu, Yunyan District, Guiyang city, Guizhou Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
贵州中医药大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Guizhou University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省贵阳市市东路50号贵州中医药大学 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Guizhou University of Traditional Chinese Medicine, 50 Shidong Road, Guiyang city, Guizhou Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究生课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
Postgraduate project |
||||||||||||||||||||||
|
研究疾病: |
勃起功能障碍 |
||||||||||||||||||||||
|
Target disease: |
Erectile dysfunction |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1、通过观察治疗前后的IIEF-5(国际勃起功能问卷)、中医临床证候积分、SAS、SDS从主观量表上验证针刺治疗ED的临床疗效; 2、通过观察治疗前后的血清睾酮水平(T)从客观指标上验证针刺治疗ED的临床疗效; 3、通过观察记录不良事件评价针刺治疗ED的安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To verify the clinical efficacy of acupuncture in the treatment of ED from subjective scale by observing IIEF-5(International Erectile Function Questionnaire), TCM clinical syndrome score, SAS and SDS before and after treatment; 2. Verify the clinical effect of acupuncture on ED by observing the serum testosterone level (T) before and after treatment. 3. To evaluate the safety of acupuncture for ED by observing and recording adverse events. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合上述诊断标准; |
||||||||||||||||||||||
|
Inclusion criteria |
① Meet the above diagnostic criteria; |
||||||||||||||||||||||
|
排除标准: |
①不符合上诉诊断标准和纳入标准者; |
||||||||||||||||||||||
|
Exclusion criteria: |
① Those who do not meet the diagnostic criteria for appeal and inclusion criteria; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2023-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-11 00:00:00 至 To 2023-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用excel随机数字表法,生成60个随机数字,平均分成2组,并确定每个序列号的分组,每组个30名受试者;将代表不同治疗方案的代码(①、②)分别放入相应的编有序列号的不透明信封,受试者入组顺序抽取信封,由研究者打开信封,按代码代表的治疗方案进行治疗。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using excel random number table method, 60 random numbers were generated, divided into 2 groups on average, and the grouping of each serial number was determined, with 30 subjects in each group. The codes representing different treatment plans (① and ②) were put into corresponding opaque envelopes with seri |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开原始数据日期;试验完成后6个月内公开;公开内容:原始记录的数据和研究计划书。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Date of disclosure of raw data; Public within 6 months after the completion of the test; Public content: original recorded data and research proposal. 修改翻译结果 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由专业数据采集者采集数据;课题组将完整地保留。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection by professional data collectors; The research group will remain intact. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |